ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2003
The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2024Pooled it
- Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study.PharmacoEconomics - open · 2024Article
- Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice.Health economics review · 2020Article
- Economic Evaluation of Community-Based HIV Prevention Programs in Ontario: Evidence of Effectiveness in Reducing HIV Infections and Health Care Costs.AIDS and behavior · 2016Article
- Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study.The European journal of health economics : HEPAC : health economics in prevention and care · 2013Article
- Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa.Journal of acquired immune deficiency syndromes (1999) · 2013Article
- Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2012Article
- The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period.AIDS research and treatment · 2012Article
- Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.PloS one · 2012Article
- Pay now or pay (more) later: tracking the costs of hepatitis C infection.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2010Article
- Health care costs associated with hepatitis C: a longitudinal cohort study.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2010Article
- Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2010Article
- The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.BMC health services research · 2009Article
- Inpatient charges among HIV/AIDS patients in Rhode Island from 2000-2004.BMC health services research · 2009Article
- The cost-effectiveness of Vancouver's supervised injection facility.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
- Healthcare utilization of patients accessing an African national treatment program.BMC health services research · 2007Article
- Managing Medicare's HIV caseload in the era of suppressive therapy.American journal of public health · 2007Article
- Brief communication: economic comparison of opportunistic infection management with antiretroviral treatment in people living with HIV/AIDS presenting at an NGO clinic in Bangalore, India.MedGenMed : Medscape general medicine · 2006Article
- The HAART side of resource allocation.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDetermining the direct cost of providing medical care to patients with HIV/AIDS is important for both short-term and long-term decision-making and for appropriate resource allocation. We aimed to categorize and measure the direct costs of medical care provided to the entire HIV-positive population receiving care in southern Alberta between 1995 and 2001.
methodsWe collected all patient-specific direct costs including the cost of pharmaceutical drugs (HIV and non-HIV drugs), outpatient care (including physician costs and laboratory testing), inpatient (in-hospital) care and home care (acute, long-term, palliative) from primary sources for all patients between April 1995 and April 2001. We determined cost per patient per month (PPPM) adjusted to 2001 Canadian dollars.
resultsSince 1995, the direct cost of providing medical care to patients with HIV/AIDS has increased primarily as a result of increased antiretroviral drug costs both in absolute and in PPPM terms. Mean PPPM expenditures increased from 655 Canadian dollars in 1995/96, that is, before the use of highly active antiretroviral therapy (HAART), to 1036 Canadian dollars in 1997/98 when HAART was widely used. During the following 3 years, mean overall PPPM costs remained stable. Antiretroviral drugs accounted for 30% (198 Canadian dollars PPPM) of the total cost in 1995/96 increasing to 69% (775 Canadian dollars PPPM) in 2000/01. Inpatient, outpatient and home care costs decreased in both percentage and cost PPPM between 1995/96 and 2000/01 from 26% to 10%, 27% to 14% and 8% to 3% respectively.
interpretationThe cost of providing medical care to HIV-positive patients continues to increase, although the burden of costs is distributed differently from before the introduction of HAART, with the costs of drug therapy offsetting the costs of inpatient care and home care. Careful consideration of all aspects of direct costing data is needed when any health economic policy issues are examined.
Indexed as
Identifiers
12874156PMC164974W2119767689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.